Study drug for acute ischemic stroke started within 24 hours
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether an investigational study drug can improve outcomes after an acute ischemic stroke (a stroke caused by blocked blood flow). You may be eligible if you are able to start treatment quickly after symptom onset and have a moderate stroke severity on a standard stroke exam.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 to 90 years old and weigh 40 to 166 kg
- Start study treatment within 24 hours of the last time you were known normal (when stroke symptoms began)
- Have a stroke severity score (NIHSS) between 5 and 15 at study start (or it worsened to that range)
- Have no bleeding in the brain on CT/MRI scans done at screening (and repeat imaging if needed)
- Your pre-stroke function was good (mRS 0 to 1)
- Not be scheduled for a procedure to remove a clot (mechanical thrombectomy) for this stroke
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the clot-busting drug tenecteplase can help people with a moderate to severe stroke when given 24 to 72 hours after symptoms began. It aims to see if this later treatment window can improve recovery and reduce disability.
This trial tests a new approach for treating acute ischemic stroke within 4.5 hours of symptoms starting. It combines a special mobile stroke unit that delivers early brain-protecting medicine with standard clot-busting or clot-removal procedures, to see if this can improve recovery.
This trial tests if giving a second dose of a clot-busting drug (tenecteplase) helps people who had a stroke and didn't improve much after the first dose. You must receive the second dose within 4.5 hours of your stroke symptoms starting.
This trial tests an investigational drug called LT3001 for people who have had an acute ischemic stroke (a type of stroke caused by a blocked blood vessel in the brain). The drug is given within 24 hours of the stroke to help reduce the damage and improve recovery. Participating could offer access to a new treatment option that may help improve outcomes.
This trial tests a single dose of a new clot-dissolving medicine for people who had a stroke 4.5 to 24 hours ago. It may help if you cannot have standard treatments like a clot-removal procedure or other clot-busting drugs.
This trial tests an investigational injection called KPCXM18 for people having an acute ischemic stroke. It is given within 12 hours of symptom onset, in addition to standard clot-dissolving treatment, to see if it improves recovery and safety.
Hear when a new Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.